Drug intelligence / Profile preview

Rujiexiao

Development stage: Unknown
Lead developer: Tailong
Administration: Oral

Overview

Rujiexiao is a Traditional Chinese Medicine (TCM) preparation developed by Henan Tailong Pharmaceutical Co., Ltd., primarily in the form of granules. It is designed to treat breast hyperplasia and breast nodules, specifically targeting the Liver Qi Stagnation and Phlegm Coagulation pattern in TCM theory. The formulation works by soothing the liver, regulating Qi circulation, and resolving phlegm to alleviate breast pain and reduce the size of nodules. It has undergone Phase II clinical evaluation in China to assess its efficacy and safety in patients with these conditions.

Brand names: Rujiexiao Granules
Other names: 乳解消颗粒

Targets

SYK (Spleen Tyrosine Kinase)OPRT (Orotidine 5'-phosphate decarboxylase)

Beyond the preview

Go deeper on Rujiexiao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rujiexiao.

Explore the full profile